Mr. Mike Seckler reports

SALONA GLOBAL FINALIZES NAME CHANGE TO EVOME MEDICAL TECHNOLOGIES TO REFLECT TURN AROUND AND NEW INNOVATION FOCUS; RESTRUCTURES BOARD OF DIRECTORS

Salona Global Medical Device Corp. will change its corporate name change to Evome Medical Technologies Inc. on Jan. 22, 2024, and trading of the company's common shares on the TSX Venture Exchange will commence under the ticker symbol EVMT on Jan. 22, 2024. The name change reflects the company's commitment as a high-tech physical therapy medical device company. Appointed in June, 2023, Mike Seckler has successfully implemented strategic imperatives that have resulted in the establishment of the new Evome Medical Technologies:

• 18.5-per-cent revenue growth for the quarter ending Sept. 30, 2023 (compared with the previous quarter), management expects revenue growth to continue into 2024;
• 29-per-cent gross profit growth for the quarter ending Sept. 30, 2023 (compared with the previous quarter), management expects gross profit growth to continue into 2024;
• Generated positive adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $749,425 for the quarter ending Sept. 30, 2023, management expects positive adjusted EBITDA growth to continue into 2024;
• Announced plans to launch two new Biodex products, the SpaceTek Knee (Nov. 17, 2023) and the Biodex Reactive Step Trainer (December 18, 2023), into the private physical therapy market that has 10 times the amount of customers than the institutional market current Biodex products are marketed to;
• Reduced Biodex acquisition debt by $428,237 (U.S.) in the third quarter and extended the balance of the debt until July, 2025, pursuant to the previously announced forbearance agreement;
• Restructured the management team and board of directors with a focus on innovation focused managers and board members with the most recent change coming from Leslie Cross retiring from the board of directors;
• Refocused the capital markets communication with new investor presentation in advance of attending the CEM AlphaNorth Capital Event in Nassau, Bahamas from Jan. 19 to 21, 2024.

Mr. Seckler expressed, "Now that we generated revenue growth and adjusted EBITDA, we are prioritizing the creation of new products and strengthening our ability to innovate in the rapidly expanding physical rehabilitation and recovery market." In closing, Mr. Seckler stated: "Our focus is on product innovation and we are structuring Evome to be in a position for continuous growth. The recent changes, such as reducing debt, adding new distribution agreements and the restructuring of the board, solidify our commitment to sustained success."

We seek Safe Harbor.